Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Three decades of heart transplantation: experience and long-term outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early Coronary Atherosclerosis in Women With Previous Preeclampsia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Treatment with the sodium-glucose cotransporter 2 inhibitor (SGLT-2i) empagliflozin significantly reduces cardiovascular events in patients with type 2 diabetes (T2D); however, the mechanisms behind the reduction in cardiovascular (CV) events are unknown. We investigated whether SGLT-2i treatment affected central hemodynamics during rest and exercise in 34 patients with diabetes in this investigator-initiated, randomized, placebo-controlled, double-blinded trial. The primary end point was change in pulmonary capillary wedge pressure (PCWP) at a submaximal ergometer workload (25 W) after 13 weeks of SGLT-2i treatment (25 mg once daily) compared with placebo. Secondary end points included changes in resting hemodynamics. Baseline and follow-up hemodynamic assessments were performed at rest, submaximal exercise (25 W), and peak exercise using right heart catheterization. Treatment with empagliflozin for 13 weeks in patients with T2D at high CV risk did not reduce left heart filling pressure more than placebo at submaximal exercise. At rest, we observed that empagliflozin reduced PCWP at a magnitude of clinical significance.

OriginalsprogEngelsk
TidsskriftDiabetes
Vol/bind71
Udgave nummer4
Sider (fra-til)812-820
Antal sider9
ISSN0012-1797
DOI
StatusUdgivet - 1 apr. 2022

Bibliografisk note

© 2022 by the American Diabetes Association.

ID: 75904736